News

XIFAXAN is indicated for the treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating. Rifaximin is a gut-selective antibiotic with negligible systemic absorption and broad-spectrum activity

BioSante Pharma is developing LibiGel as a treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. The efficacy trials are being conducted

The success could help make TRO40303 the first treatment to reduce cardiac reperfusion injury which leads to morbidity and mortality myocardial infarction. The study was aimed at assessing

The Enabling the EHR Integration Suite makes it possible to capture detailed specialty data and images from all areas of the cardiovascular service line and beyond and export

Michrom is a provider of liquid chromatography (LC) instrumentation, accessories and consumables for applications in the life science, chemical and applied markets. Bruker Chemical & Applied Markets division

The company claims that Krystexxa is now the first and only therapy available to address this unmet medical need. Savient Pharma CEO John Johnson said since receiving FDA

CEQ508 is currently in a Phase 1b/2a clinical development program and is intended for the treatment of Familial Adenomatous Polyposis. CEQ508 comprises attenuated bacteria that are engineered to

NorLevo is an oral emergency contraceptive, which is taken within 72 hours after unprotected sexual intercourse or contraceptive failure to prevent unwanted pregnancy. Sosei has taken over the

Tranzyme Pharma’s Ulimorelin is indicated for the management of postoperative ileus (POI) in hospital and acute care settings. The companies are expecting to enroll about 300 bowel surgery